Itopride and pantoprazole outcomes in diabetic gastroparesis trial (IPOD trial)
- PMID: 19370958
Itopride and pantoprazole outcomes in diabetic gastroparesis trial (IPOD trial)
Abstract
The most common cause of gastroparesis is diabetes mellitus. The present study was carried out to asses the combination of itopride and pantoprazole in the treatment of diabetic gastroparesis. The study was an open label, multicentre, conducted in 743 patients with diabetic gastroparesis for a period of 3 weeks. The efficacy parameters included nausea, vomiting, early satiety, bloating, postprandial fullness, epigastric pain and regurgitation. The patients were evaluated based on the frequency and severity of symptoms and compared with the baseline scores. There were significant improvement in severity as well as the frequency of all the symptom parameters of the disease (p<0.001). The physicians' evaluation to the therapy was rated either excellent or good.
Similar articles
-
Rabeto plus: a valuable drug for managing functional dyspepsia.J Indian Med Assoc. 2008 Nov;106(11):752-4. J Indian Med Assoc. 2008. PMID: 19368103 Clinical Trial.
-
Management of diabetic gastroparesis.J Indian Med Assoc. 2005 Mar;103(3):184, 186. J Indian Med Assoc. 2005. PMID: 16173296 Review.
-
Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD).Neurogastroenterol Motil. 2012 May;24(5):456-63, e215-6. doi: 10.1111/j.1365-2982.2012.01879.x. Epub 2012 Jan 27. Neurogastroenterol Motil. 2012. PMID: 22284754
-
Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data.Aliment Pharmacol Ther. 2011 Mar;33(6):679-88. doi: 10.1111/j.1365-2036.2010.04567.x. Epub 2011 Jan 7. Aliment Pharmacol Ther. 2011. PMID: 21214610 Clinical Trial.
-
Motilides: a long and winding road: lessons from mitemcinal (GM-611) on diabetic gastroparesis.Regul Pept. 2009 Jun 5;155(1-3):18-23. doi: 10.1016/j.regpep.2009.03.011. Epub 2009 Apr 2. Regul Pept. 2009. PMID: 19345243 Review.
Cited by
-
Pharmacologic Treatment for Pediatric Gastroparesis: A Review of the Literature.J Pediatr Pharmacol Ther. 2016 Mar-Apr;21(2):120-32. doi: 10.5863/1551-6776-21.2.120. J Pediatr Pharmacol Ther. 2016. PMID: 27199619 Free PMC article. Review.
-
Efficacy and safety of pantoprazole and itopride in patients with overlap of gastroesophageal reflux disease and dyspepsia: A prospective, open-label, single-arm pilot study.JGH Open. 2024 Feb 2;8(2):e12988. doi: 10.1002/jgh3.12988. eCollection 2024 Feb. JGH Open. 2024. PMID: 38344252 Free PMC article.
-
The efficacy and safety of itopride in feeding intolerance of critically ill patients receiving enteral nutrition: a randomized, double-blind study.BMC Gastroenterol. 2021 Mar 19;21(1):126. doi: 10.1186/s12876-021-01712-w. BMC Gastroenterol. 2021. PMID: 33740892 Free PMC article. Clinical Trial.
-
A Prospective Multicentric Postmarketing Observational Study to Characterize the Patient Population with Reduced Gastrointestinal Motility among Indian Diabetic Patients Receiving Itopride: The Progress Study.Int J Appl Basic Med Res. 2019 Jul-Sep;9(3):148-153. doi: 10.4103/ijabmr.IJABMR_351_18. Int J Appl Basic Med Res. 2019. PMID: 31392177 Free PMC article.
-
Efficacy and safety of itopride SR for upper gastrointestinal symptoms in patients with diabetic gastroparesis: real-world evidence from Pakistan.Drugs Context. 2023 Dec 19;12:2023-6-4. doi: 10.7573/dic.2023-6-4. eCollection 2023. Drugs Context. 2023. PMID: 38148829 Free PMC article.